Health and Safety at the 2023 ASPHO Conference
Updated on December 15, 2022
ASPHO is committed to the health and safety of all ASPHO Conference participants. We believe that we can once again safely bring together our community with appropriate protocols in place. ASPHO will implement precautions to provide a safe meeting experience for all attendees, presenters, partners, and staff.
Health and Safety Protocols for in-person attendance at the 2023 ASPHO Conference include:
- Provide verification of having completed a COVID-19 vaccine primary series* as defined by the CDC is required for all in-person conference attendees, presenters, exhibitors, partners, press, and staff prior to traveling to Fort Worth, TX. Details will be forthcoming regarding the process of providing documentation.
- All booster doses recommended for you by the CDC are strongly encouraged, but not required.
- Masks indoors are encouraged in meeting rooms and common areas.
- Attendees are strongly encouraged to conduct an antigen test no more than one day prior to travel to the ASPHO Conference
For attendees who are not vaccinated, a virtual option will be available. ASPHO will not accept exemptions or proof of negative tests in lieu of verified vaccination status for onsite participation.
By registering for the in-person Conference in Fort Worth, you agree to abide by all Health and Safety Protocols instituted or modified by ASPHO and the venues during the conference dates of May 10-13, 2023. Individuals not in compliance with all Health and Safety Protocols may be asked to leave the Conference and refunds will not be provided.
*Completing the primary series means two weeks after the second dose in a two-dose series, or two weeks after a single-dose vaccine. Accepted vaccinations include those authorized for emergency use or FDA-Approved by the U.S. Food and Drug Administration (i.e., Pfizer-BioNTech, Moderna, and Novavax COVID-19 vaccines), and COVID-19 vaccines that have met the necessary criteria for safety and efficacy by the World Health Organization (i.e., AstraZeneca/Oxford, Sinopharm, Sinovac, etc).
For additional information, visit: